Orgenesis issues warrant for 3.29M shares under $1M loan drawdown

Orgenesis Inc.

Issued Alpha Warrant for 3,289,490 common shares at $250,000 aggregate exercise price.
Warrant is exercisable for three years from January 9, 2026.
Part of a $1M drawdown under the September 2025 Convertible Loan Agreement with Alpha Prosperity Fund SPC.
Shares issuable upon exercise are unregistered, exempt under Section 4(a)(2) of the Securities Act.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Orgenesis Inc. entered into Convertible Loan Agreement with Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P valued at $1,000,000 convertible loan, a $10,000,000 credit facility (effective 2025-09-10).

Action: entry
Agreement: credit facility
Counterparty: Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P
Value: $1,000,000 convertible loan, a $10,000,000 credit facility
Effective: 2025-09-10

Exact text from the filing

Orgenesis Inc. (the “Company”) entered into that certain Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, the Company and Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P (the “Lender”) with respect to a $1,000,000 convertible loan, a $10,000,000 credit facility

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001493152-26-003501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.